Navigation Links
NBTY Reports Second Quarter Results
Date:4/23/2009

Accrued expenses and other liabilities (20,843) (10,946) Net cash provided by operating activities 56,226 114,813 Cash flows from investing activities: Purchase of property, plant and equipment (35,639) (21,693) Purchase of available-for-sale investments - (159,884) Proceeds from sale of available-for-sale investments - 248,728 Cash paid for acquisitions, net of cash acquired (264) (5,072) Escrow refund, net of purchase price adjustments 11,989 - Net cash (used in) provided by investing activities (23,914) 62,079 Cash flows from financing activities: Principal payments under long-term debt agreements and capital leases (16,785) (481) Proceeds from borrowings under the Revolving Credit Facility 60,000 - Principal payments under the Revolving Credit Facility (115,000) - Excess income tax benefit from exercise of stock options - 4,984 Proceeds from stock options exercised 6 3,852 Purchase of treasury stock (subsequently retired) - (171,008) Net cash used in financing activities (71,779) (162,653) Effect of exchange rate changes on cash and cash equivalents (6,912) (2,233) Net (decrease) increase in cash and cash equivalents (46,379) 12,006 Ca
'/>"/>
SOURCE NBTY, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Blue Cross Blue Shield of Michigan announced ... Care Network and BCN,s current vice president for products ... the state,s largest health maintenance organization when Carlson retires ... was announced today by Daniel J. Loepp, president and ... The appointment is pending formal approval from the ...
(Date:12/17/2009)... advice most effective when it comes from physician, study ... pediatrician,s advice has the most influence in convincing parents ... sleep in order to prevent sudden infant death syndrome, ... government launched the "Back to Sleep" campaign in 1994, ... sleep time has increased from 25 percent to 70 ...
(Date:12/17/2009)... the Fisher Theatre on Dec. 17 for the Detroit-area,premiere of the ... be the real stars of the show. , , ... ... stage at the Fisher Theatre on Dec. 17 for the Detroit-area ... and cancer survivors will be the real stars of the ...
(Date:12/17/2009)... thought-leaders in inflammatory bowel disease (IBD) research were awarded ... Awards at its 2009 Advances in Inflammatory Bowel Diseases ... Florida on December 4th. , ... ... 2009 -- Three clinical and scientific thought-leaders in inflammatory ...
(Date:12/17/2009)... Reportlinker.com announces that a new ... catalogue: ,, http://www.reportlinker.com/p0169956/Top-Ten-Worlds-Leading-Animal-Health-Companies.html ,, ... animal health industry executives with strategically significant ... the development and implementation of effective marketing ... include: ,, To establish a ...
Breaking Medicine News(10 mins):Health News:Doctor's Orders Influence Baby's Sleep Position 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 2Health News:Jersey Boys' Premiere Benefits Cancer Patients While Launching Beaumont Hospitals Fundraising Campaign 3Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 2Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 3Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 4Health News:Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases 5Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 2Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 3Health News:Reportlinker Adds Top Ten World's Leading Animal Health Companies 4
... Tommy John teams up with Long Island, NY based New Vitality to ... to address the lifestyle needs of active men and women of all ... ... (PRWEB) December 11, 2008 -- The name of baseball legend Thomas Edward ...
... provider of Electronic Medical Record and practice billing solutions for the ... the company as Chief Commercial Officer. Flormann brings 25 years ... and business and market development to Glenwood Systems. , ... ...
... DC, December 11, 2008-- An independent review investigating the ... has found that the campaign has been associated with ... the December issue of Prevention Science , a ... (SPR)., The Montana Meth Project (MMP) was created in ...
... Inc. (Nasdaq: VTAL ) , ... has named Ray A. Ghanbari, Ph.D., Executive Vice President of ... to President and Chief Executive Officer Michael H. Carrel. In ... marketing, corporate development and driving strategic business planning. , ...
... Dec. 10 Basic government services are not being provided ... and other communicable diseases are rampant. Staggering inflation and unemployment ... that 300,000 people remain at risk of cholera, which is ... lack of functioning sanitation services. To date, the outbreak has ...
... Some are genetically driven to eat more calories, study ... people may be genetically driven to seek out more ... Dec. 11 issue of the New England Journal ... a particular gene variant tend to eat more energy-dense ...
Other Medicine News:Health News:Tommy John Is Now 'Pitching' For GoFlex Joint Formula 2Health News:Tommy John Is Now 'Pitching' For GoFlex Joint Formula 3Health News:Glenwood Systems, LLC Appoints Ron Flormann Chief Commercial Officer 2Health News:Success of anti-meth ads questioned by study 2Health News:Success of anti-meth ads questioned by study 3Health News:Vital Images Names Healthcare Veteran Ray Ghanbari Executive Vice President of Strategy and Products 2Health News:Vital Images Names Healthcare Veteran Ray Ghanbari Executive Vice President of Strategy and Products 3Health News:Gene May Make Kids Crave Junk Food 2Health News:Gene May Make Kids Crave Junk Food 3
(Date:12/17/2009)... -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced ... four weeks for the first dose cohort, 200 mg bid, ... with pegylated interferon and ribavirin (SOC) in HCV patients. ... of virus (<15 IU/ml) at week 4, known as ... compared to 20% of patients receiving placebo plus SOC. ...
(Date:12/17/2009)... -- Pharmaceutical Institute today announced that it has ... specializing in life science courseware. These assets, ... Institute,s already extensive library of training resources. ... of specialized training solutions for the pharmaceutical and ... Financial terms of the agreement were not ...
(Date:12/17/2009)... -- BASF today announced that the ... of Aseptrol® S10 - Tab in H1N1 sanitization ... schools, hospitals, government buildings, retail and restaurants, and ... based on Chlorine dioxide (CIO2) release technology. ,, ... spectrum disinfectant as stated in the EPA label ...
Breaking Medicine Technology:ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 2ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 3ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 4ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 5ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 6ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 7Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 2Pharmaceutical Institute Acquires E-Learning Assets from GeneEd, Inc. 3BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 2BASF's Aseptrol(R) S10 - Tab Receives EPA Approval For H1N1 Sanitization Label 3Studies Quantify Cancer Risks From CT Scans 63248 1Studies Quantify Cancer Risks From CT Scans 63248 2Studies Quantify Cancer Risks From CT Scans 63248 3Studies Quantify Cancer Risks From CT Scans 63248 4UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 63244 1UNC scientists coordinate study of link between insulin use and cancer in people with diabetes 63244 2Scientists isolate new antifreeze molecule in Alaska beetle 11142 1Scientists isolate new antifreeze molecule in Alaska beetle 11142 2
... DIEGO, Dec. 8, 2008 Forest Laboratories, Inc. (NYSE: ... CYPB ) today announced positive top-line results ... study of milnacipran for the management of fibromyalgia. ... previous phase III trials, showed that milnacipran demonstrated a ...
... Dec. 8 Cell Therapeutics, Inc. (CTI),(Nasdaq ... follow-up data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line ... of Hematology (ASH) 50th Annual Meeting by,Morschhauser, ... progression-free,survival (PFS) following Zevalin consolidation therapy for ...
Other Medicine Technology:Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia 5Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5
... you need quick, accurate, convenient, and cost-effective ... VITROS DT60 II Chemistry System. This easy-to-use ... back-up laboratory testing requirements. And it helps ... better patient outcomes, reduced overall costs, and ...
... provides power and efficiency to ... volume testing facilities. With fast ... results per hour, the Vitros ... the full complement of Vitros ...
... Abbott entered the Therapeutic Drug Monitoring ... the TDx. Still in use today, this ... Polarization Immunoassay) to measure serum drug concentration ... the treatment of different diseases, often exhibit ...
AxSYM Plus provides cutting-edge ergonomics and smart new features that mean increased ease-of-use and enhanced reliability. Also, advanced software means less operator intervention and high-integrit...
Medicine Products: